Nasdaq

Chemomab Therapeutics Announces FDA Alignment on Phase 3 Trial Design for Nebokitug as Potential First Treatment for Primary Sclerosing Cholangitis

Chemomab Therapeutics has announced that it has successfully completed its End-of-Phase 2 meeting with the FDA, aligning on the design of a single Phase 3 trial for its lead product candidate, ...
Nasdaq

IMUNON, Inc. Announces Presentation of Promising Overall Survival Data from Phase 2 OVATION 2 Study for Advanced Ovarian Cancer and Initiation of Phase 3 Trial Sites for IMNN-001

Highly encouraging overall survival data from the Phase 2 OVATION 2 Study of IMNN-001 has been accepted for oral presentation at the prestigious ASCO Annual Meeting, indicating strong interest in the ...
Hosted on MSN

Acurx signals progress in Phase 3 ibezapolstat program with $12M credit line following regulatory alignment

David Luci, President and CEO, highlighted several significant developments, including the closing of a $2.5 million registered direct offering and the receipt of positive regulatory guidance from the ...
Seeking Alpha

Exclusive BAC Article: Elicio Therapeutics; Q3 Of 2025 ELI-002 PDAC Data, Phase 3 FDA Alignment 2nd Half Of 2025 And Catalysts

I believe that a good speculative biotech to go over for the "Exclusive BAC Subscribers Article" would be Elicio Therapeutics (ELTX). The reason why I want to go over this biotech next is because it ...
Hosted on MSN

BioAtla outlines $800M peak sales target for Oz-V as FDA alignment paves way for phase III launch

Jay Short, Co-Founder, CEO & Chairman, emphasized that BioAtla is "currently in advanced stages to finalize a strategic transaction with a potential partner by year-end." He announced FDA alignment on ...

Solid Biosciences: Positive FDA Meeting For SGT-003 Sets Up Next Milestones

Solid Biosciences Inc. is a Strong Buy driven by positive FDA alignment on phase 3 IMPACT DUCHENNE trial for SGT-003. Read ...